论文信息 - LBA4_PRRANGE: A randomized, double-blind, placebo-controlled phase 3 study of docetaxel (DOC) with or without ramucirumab (RAM) in platinum-refractory advanced or metastatic urothelial carcinoma - 字舞流文

LBA4_PRRANGE: A randomized, double-blind, placebo-controlled phase 3 study of docetaxel (DOC) with or without ramucirumab (RAM) in platinum-refractory advanced or metastatic urothelial carcinoma

T. Powles | H. Nishiyama | C. Sternberg | D. Petrylak | R. Walgren | B. Alekseev | A. Drakaki | E. Yu | M. V. D. Heijden | D. Castellano | A. Zimmermann | K. Chi | O. Hamid | K. Bell-McGuinn | R. Wit | S. Hussain | A. Bamias | N. Matsubara | I. Percent | A. Flechon